NCT06563856View on ClinicalTrials.gov

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions
BioavailabilityBioequivalence
Interventions
DRUG

TEPEZZA

Administered as a SubQ injection or IV injection.

DRUG

EDP

Administered as a SubQ injection.

Trial Locations (1)

89113

PPD Development, Las Vegas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06563856 - A Study of TEPEZZA Subcutaneous Administration in Healthy Adults | Biotech Hunter | Biotech Hunter